Pharmaceuticals, Biotechnology and Life Sciences
A drug widely used to cure malaria has failed for the first time in patients being treated in Britain, raising questions over whether the parasite is becoming resistant to drugs, researchers said on Tuesday
Onxeo, an oncology French-based focused drugmaker and a cancer researcher, the Institut Curie, have kicked off several cancer studies, to test the combination of radiotherapy, DNA repair inhibitors and immunotherapy.
GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.
Ipsen has signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of the company in the future.
European Commission has approved Novartis’s Votubia (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose…
TiGenix has enrolled the first patient and treated in a Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).
Novo Nordisk and University of Oxford have expanded their partnership on researching type 2 diabetes, and will open a new research centre in Oxford.
Shield Therapeutics has appointed Capita Registrars Limited as company secretary, after Richard Jones has officially resigned.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Pfizer’s Xeljanz (tofacitinib citrate)…
InnovaDerma has appointed Kieran Callan as a Non-Executive Director with immediate effect, succeeding Garry Lemair who stepped down from the…